Meeting
2022 ASCO Annual Meeting
Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.
Authors
Alexandra Ikeguchi
University of Oklahoma, Oklahoma City, OK
Alexandra Ikeguchi , Joseph J. Sacco , Jason J. Luke , T.R. Jeffry Evans , Brendan D. Curti , Kevin B. Kim , Shaad Essa Abdullah , Claire Watkins , Ozgur Karakuzu , Paul D. Nathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Other Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT03070392
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9584)
DOI
10.1200/JCO.2022.40.16_suppl.9584
Abstract #
9584
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
First Author: Richard D. Carvajal
Poster
2021 ASCO Annual Meeting
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
First Author: Jessica Cecile Hassel
Poster
2021 ASCO Annual Meeting
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
First Author: Marlana Orloff
Poster
2023 ASCO Annual Meeting
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
First Author: Kamaneh Montazeri